Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial

Phase 2Halneuron®Positive

AI Analysis

Summary

Dogwood announced completion of enrollment in its Phase 2b Halneuron trial with 239 patients, meeting the upper end of the planned enrollment target range.

Clinical Trial Data

Phase

Patients

239

Importance:5/10

Sentiment:

0.60

clinical trialenrollmentPhase 2bHalneuron

Related Companies

$CBDY

Read the original article

Published by GlobeNewswire Clinical Studies on September 14, 2026 12:45 PM

Read Original